PP
KALV

Paloma Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Paloma Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,924
Closed -$208K – 692
2024
Q3 		$208K Buy
+17,924
New +$225K 0.01% 963
2016
Q3 		– Sell
-2,905
Closed -$27K – 1989
2016
Q2 		$27K Buy
+2,905
New +$33.6K ﹤0.01% 2117

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Paloma Partners's KALV Position: Q4 2024 in Review

Paloma Partners sold out of KalVista Pharmaceuticals (KALV) in Q4 2024, closing a stake of 17,924 shares — an estimated $208K sold.

Paloma Partners first reported a position in KALV in Q2 2016 and held it in 2 quarters. The position peaked at $208K in Q3 2024. 130 funds tracked by Wall St. Rank hold KALV as of Q4 2024.

  • Paloma Partners reported no remaining KalVista Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 17,924 KalVista Pharmaceuticals shares in Q4 2024, an estimated $208K.
  • Paloma Partners first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Paloma Partners's KalVista Pharmaceuticals position peaked at $208K in Q3 2024.
  • 130 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.